Suchitra Acharya
Overview
Explore the profile of Suchitra Acharya including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
206
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Citla-Sridhar D, Ahuja S, Sidonio R, Chitlur M, Sharathkumar A, Tobase P, et al.
Haemophilia
. 2025 Mar;
PMID: 40052405
Background: Despite reports of elevated rates of osteoporosis and fractures in persons with haemophilia (PwH) and von Willebrand disease (PwVWD), routine bone health screening using dual-energy X-ray absorptiometry (DEXA) scans...
2.
Wilson H, Mosha M, Miller A, Betensky M, Amankwah E, Fargo J, et al.
Semin Thromb Hemost
. 2024 Sep;
51(3):343-347.
PMID: 39299256
No abstract available.
3.
Youkhana K, Batsuli G, Acharya S, Khan O, Tran D, Dvorak A, et al.
Haemophilia
. 2024 Sep;
30(6):1321-1331.
PMID: 39297369
Introduction: The management of bleeding events (BEs) in haemophilia A (HA) and B (HB) patients with inhibitors necessitates the use of bypassing agents. The recombinant factor VIIa bypassing agent eptacog...
4.
Roberts J, Escobar M, Acharya S, Hwang N, Wang M, Hale S, et al.
Haemophilia
. 2024 May;
30(4):970-980.
PMID: 38751022
Introduction: Gastrointestinal (GI) bleeding events (BEs) in von Willebrand disease (VWD) are difficult to diagnose and often recurrent. Limited data from clinical trials has led to lack of consensus on...
5.
Morgan D, Kang J, Levine C, Acharya S
J Pediatr Pharmacol Ther
. 2024 Apr;
29(2):130-134.
PMID: 38596416
Objectives: Enoxaparin for the prevention of venous thromboembolism (VTE) in pediatric patients is -typically dosed twice a day. The use of once-daily dosing like that used in adult patients is...
6.
Casini A, Abdul Kadir R, Abdelwahab M, Manco-Johnson M, Raut S, Ross C, et al.
J Thromb Haemost
. 2024 Jan;
22(5):1516-1521.
PMID: 38266678
Congenital fibrinogen disorders (CFDs) are a heterogeneous group of rare congenital quantitative and/or qualitative fibrinogen deficiencies. The spectrum of molecular anomalies is broad, leading to several subtypes of fibrinogen disorders...
7.
Vagrecha A, Zhang M, Acharya S, Lozinsky S, Singer A, Levine C, et al.
Biology (Basel)
. 2022 Mar;
11(3).
PMID: 35336791
Multisystem inflammatory syndrome in children (MIS-C) affects few children previously infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In 2020, 45 children admitted to our hospital for MIS-C underwent...
8.
Berntorp E, LeBeau P, Ragni M, Borhany M, Abajas Y, Tarantino M, et al.
Haemophilia
. 2022 Mar;
28(3):453-461.
PMID: 35263495
Introduction: The B-Natural study is a multicentre, multinational, observational study of haemophilia B (HB) designed to increase understanding of clinical manifestations, treatment and quality of life (QoL). Aim: To characterise...
9.
Swaminathan N, Salinas-Luna V, Acharya S, Sharathkumar A
Haemophilia
. 2021 Sep;
27(6):e780-e783.
PMID: 34592042
No abstract available.
10.
Astermark J, Holstein K, Abajas Y, Kearney S, Croteau S, Liesner R, et al.
Haemophilia
. 2021 Jun;
27(5):802-813.
PMID: 34118102
Introduction: Inhibitors develop less frequently in haemophilia B (HB) than haemophilia A (HA). However, when present, the success of tolerization by immune tolerance induction (ITI) therapy is lower and the...